Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
This study has been completed.
First Received: March 14, 2005   Last Updated: June 4, 2009   History of Changes
Sponsor: Bayer
Information provided by: Bayer
ClinicalTrials.gov Identifier: NCT00105443
  Purpose

The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics (PK) in patients with liver cancer.


Condition Intervention Phase
Carcinoma, Hepatocellular
Drug: Nexavar (Sorafenib, BAY43-9006)
Drug: Placebo
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Overall Survival & Time to Symptomatic Progression [ Time Frame: Every 3 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Time to Progression [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
  • Disease Control Rate [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
  • Patient Reported Outcomes (PRO) as measured by total score on FACT-Hep [ Time Frame: Cycle 1 Day 1, Cycle 3 Day 1, EOT visit ] [ Designated as safety issue: No ]

Enrollment: 602
Study Start Date: March 2005
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Arm 1: Active Comparator Drug: Nexavar (Sorafenib, BAY43-9006)
400 mg BID BAY 43-9006
Arm 2: Placebo Comparator Drug: Placebo
400 mg BID Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages eligible for study: 18 years and above, Genders eligible for study: both
  • Patients who have a life expectancy of at least 12 weeks
  • Patients with histologically or cytologically documented HCC
  • Patients must have at least one tumor lesion that meets both of the following criteria: (1) Accurately measured in at least one dimension according to RECIST (2) Not previously treated with local therapy
  • Patients who have an ECOG PS of 0, 1, or 2

Exclusion Criteria:

  • Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated > 3 years prior to entry is permitted
  • Renal failure requiring hemo- or peritoneal dialysis
  • History of cardiac disease
  • Active clinically serious infections
  • Known history of human immunodeficiency virus (HIV) infection
  • Known central nervous system tumors including metastatic brain disease
  • Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00105443

  Hide Study Locations
Locations
United States, Arizona
Tucson, Arizona, United States, 85724
Phoenix, Arizona, United States, 85054-4502
United States, California
Los Angeles, California, United States, 90095
Orange, California, United States, 92868-3201
Los Angeles, California, United States, 90057
Stanford, California, United States, 94305-5118
San Francisco, California, United States, 94121
United States, Connecticut
Farmington, Connecticut, United States, 06030
New Haven, Connecticut, United States, 06520-8064
United States, Florida
Gainesville, Florida, United States, 32610
Tampa, Florida, United States, 33612
Miami, Florida, United States, 33136
United States, Georgia
Atlanta, Georgia, United States, 30365
Atlanta, Georgia, United States, 30322
United States, Illinois
Chicago, Illinois, United States, 60612
Chicago, Illinois, United States, 60611
United States, Kentucky
Lexington, Kentucky, United States, 40536
United States, Michigan
Ann Arbor, Michigan, United States, 48109-0330
Detroit, Michigan, United States, 48202
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, Nebraska
Omaha, Nebraska, United States, 68198
United States, New York
Manhasset, New York, United States, 11030-3876
New York, New York, United States, 10032
New York, New York, United States, 10029
New York, New York, United States, 10032
New York, New York, United States, 10016
United States, Ohio
Canton, Ohio, United States, 44718
United States, Oregon
Portland, Oregon, United States, 97239
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Philadelphia, Pennsylvania, United States, 19140
Pittsburgh, Pennsylvania, United States, 15213-2592
United States, Texas
Houston, Texas, United States, 77030-2707
United States, Virginia
Richmond, Virginia, United States, 23249-0002
United States, Washington
Seattle, Washington, United States, 98122-4307
Seattle, Washington, United States, 98104
Argentina, Buenos Aires
Mar del Plata, Buenos Aires, Argentina, 7600
Pilar, Buenos Aires, Argentina, B1629AHJ
Argentina, Capital Federal
Bueno Aires, Capital Federal, Argentina, C1417DTB
Buenos Aires, Capital Federal, Argentina, C1120AAF
Buenos Aires, Capital Federal, Argentina, C1181ACH
Buenos Aires, Capital Federal, Argentina, C1145ADP
Argentina, Tucumán
San Miguel de Tucumán, Tucumán, Argentina, T4000GTB
San Miguel de Tucumán, Tucumán, Argentina, T4000HXU
Australia, New South Wales
Sydney, New South Wales, Australia, 2050
Sydney, New South Wales, Australia, 2145
Sydney, New South Wales, Australia, 2031
Australia, Victoria
Melbourne, Victoria, Australia, 3052
Melbourne, Victoria, Australia, 3084
Melbourne, Victoria, Australia, 3168
Belgium
BRUXELLES, Belgium, 1200
BRUGGE, Belgium, 8000
BRUXELLES, Belgium, 1070
GENT, Belgium, 9000
BRUXELLES, Belgium, 1090
LEUVEN, Belgium, 3000
Brazil
Belo Horizonte, Brazil, 30380490
Belo Horizonte, Brazil, 30180090
Sao Paulo, Brazil, 01246-903
Brazil, Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil, 90619900
Brazil, RS
Porto Alegre, RS, Brazil
Bulgaria
Stara Zagora, Bulgaria, 6000
Sofia, Bulgaria, 1527
Varna, Bulgaria, 9010
Sofia, Bulgaria, 1431
Sofia, Bulgaria, 1233
Sofia, Bulgaria, 1431
Canada, Alberta
Calgary, Alberta, Canada, T2N 4N1
Edmonton, Alberta, Canada, T6G 2C8
Canada, British Columbia
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Manitoba
Winnipeg, Manitoba, Canada, R2H 2A6
Canada, Ontario
London, Ontario, Canada, N6A 5A5
Toronto, Ontario, Canada, M5G 2C4
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Montreal, Quebec, Canada, H3A 1A1
Chile
Santiago, Chile
Chile, Región Metropolitana
Santiago de Chile, Región Metropolitana, Chile, 833-0024
Chile, RM
Santiago de Chile, RM, Chile
Croatia
Zagreb, Croatia, 10000
France
LILLE CEDEX, France, 59020
BONDY, France, 93143
SAINT HERBLAIN, France, 44805
VANDOEUVRE-LES-NANCY, France, 54500
CLICHY, France, 92110
LILLE CEDEX, France, 59020
PARIS, France, 75020
DIJON, France, 21000
RENNES CEDEX, France, 35062
MARSEILLE, France, 13005
BORDEAUX, France, 33000
RENNES CEDEX, France, 35062
Germany
Berlin, Germany, 12200
Hamburg, Germany, 20251
Germany, Baden-Württemberg
Freiburg, Baden-Württemberg, Germany, 79106
Tübingen, Baden-Württemberg, Germany, 72076
Germany, Bayern
Regensburg, Bayern, Germany, 93053
München, Bayern, Germany, 81377
München, Bayern, Germany, 81675
Germany, Hessen
Frankfurt, Hessen, Germany, 60596
Germany, Niedersachsen
Hannover, Niedersachsen, Germany, 30625
Germany, Nordrhein-Westfalen
Essen, Nordrhein-Westfalen, Germany, 45147
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
Bonn, Nordrhein-Westfalen, Germany, 53105
Germany, Rheinland-Pfalz
Mainz, Rheinland-Pfalz, Germany, 55131
Germany, Saarland
Homburg, Saarland, Germany, 66421
Germany, Sachsen-Anhalt
Halle, Sachsen-Anhalt, Germany, 06097
Magdeburg, Sachsen-Anhalt, Germany, 39112
Greece
Thessaloniki, Greece, 540 07
Thessaloniki, Greece, 54639
Thessaloniki, Greece, 56403
Greece, Attica
Haidari, Attica, Greece, 12462
Athens, Attica, Greece, 115 27
Greece, Ioannina
Dourouti-Ioannina, Ioannina, Greece, 45500
Israel
Zerifin, Israel, 70300
Petach Tikva, Israel, 49100
Tel Aviv, Israel, 64239
Haifa, Israel, 31096
Italy
Forlì, Italy, 47100
Roma, Italy, 00128
Palermo, Italy, 90129
Padova, Italy, 35128
Pisa, Italy, 56126
Bologna, Italy, 40138
Milano, Italy, 20122
Pavia, Italy, 27100
Milano, Italy, 20133
Avellino, Italy, 83100
Italy, Milano
Rozzano, Milano, Italy, 20089
Mexico
Monterrey, Mexico, 64000
México, D.F., Mexico, 06720
México, D.F., Mexico, 14050
México, D.F., Mexico, 06720
Mexico, DF
México, DF, Mexico, 14080
New Zealand
Auckland, New Zealand, 1023
Wellington South, New Zealand, 6021
Peru
Lima, Peru, 44
Comas Lima, Peru
Lima Cercado, Peru, LIMA 1
Poland
Gdansk, Poland, 80-952
Warszawa, Poland, 02-507
Warszawa, Poland, 02-781
Poznan, Poland, 61-701
Romania
Craiova Dolj, Romania, 200642
Romania, Iasi county
Iasi, Iasi county, Romania, 700111
Romania, Timis county
Timisoara, Timis county, Romania, 300223
Russian Federation
Kazan, Russian Federation, 420012
Krasnodar, Russian Federation, 350040
Ekaterinburg, Russian Federation, 620036
St. Petersburg, Russian Federation, 197758
Ekaterinburg, Russian Federation, 620102
Tolgliatti, Russian Federation
St. Petersburg, Russian Federation, 195 067
Moscow, Russian Federation, 105229
St. Petersburg, Russian Federation, 188663
Kirov, Russian Federation, 610002
Moscow, Russian Federation, 129 010
Moscow, Russian Federation, 111 020
Moscow, Russian Federation, 129110
Moscow, Russian Federation, 113 811
Moscow, Russian Federation, 105 203
Moscow, Russian Federation, 115478
Spain
Alicante, Spain, 03010
Barcelona, Spain, 08036
Barcelona, Spain, 08035
Barcelona, Spain, 08003
Barcelona, Spain, 08035
Córdoba, Spain, 14004
Madrid, Spain, 28006
Madrid, Spain, 28041
Madrid, Spain, 28034
Pamplona, Spain, 31008
Valencia, Spain, 46014
Spain, Barcelona
Badalona, Barcelona, Spain, 08916
Spain, Bizkaia
Barakaldo, Bizkaia, Spain, 48903
Switzerland
Bern, Switzerland, 3010
Genève, Switzerland, 1211
St. Gallen, Switzerland, 9007
Zürich, Switzerland, 8091
United Kingdom
Newcastle-upon-Tyne, United Kingdom, NE2 4HH
United Kingdom, Avon
Bristol, Avon, United Kingdom, BS2 8ED
United Kingdom, Greater London
London, Greater London, United Kingdom, NW3 2QG
London, Greater London, United Kingdom, SE1 9RT
United Kingdom, Oxfordshire
Oxford, Oxfordshire, United Kingdom, OX1 2JD
United Kingdom, Strathclyde
Glasgow, Strathclyde, United Kingdom, G11 6NT
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided by Bayer

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Responsible Party: Bayer HealthCare AG ( Therapeutic Area Head )
Study ID Numbers: 100554, EudraCT No: 2004-001773-26, SHARP
Study First Received: March 14, 2005
Last Updated: June 4, 2009
ClinicalTrials.gov Identifier: NCT00105443     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Bayer:
Liver Cancer
Cancer

Additional relevant MeSH terms:
Liver Diseases
Neoplasms by Histologic Type
Digestive System Neoplasms
Molecular Mechanisms of Pharmacological Action
Carcinoma, Hepatocellular
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Pharmacologic Actions
Carcinoma
Liver Neoplasms
Neoplasms
Neoplasms by Site
Digestive System Diseases
Therapeutic Uses
Adenocarcinoma
Sorafenib
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 27, 2009